The WHO has approved the first malaria vaccine

The WHO has approved the first malaria vaccine

Rights · ·

It will initially be distributed in Africa to children aged at least five months. In Kenya, Ghana and Malawi, 800,000 people have already been immunised.

With a decision that could save millions of lives, on 6 October the World Health Organization (WHO) approved the first malaria vaccine.

The drug, called Mosquirix or RTS,S, was developed by British pharmaceutical company GlaxoSmithKline (GSK) and helps the immune systems of children to defeat Plasmodium falciparum, the malarial parasite most dangerous to humans and the most widespread in Africa. The vaccine will initially be distributed only in areas of the African continent where this specific type of parasite has a particularly high transmission rate.

Even today, in sub-Saharan Africa malaria kills more than 260,000 children under the age of five every year, making it one of the leading causes of death for this age group.

Sudan
A Sudanese soldier suffering from malaria © Paula Bronstein/Getty Images

The studies and results

At present, the WHO has recommended administering four doses of the vaccine to children from five months of age. Around 2.3 million doses have already been administered to 800,000 children in Kenya, Ghana and Malawi, where a pilot distribution programme was launched in 2019. The results have shown that the drug is capable of reducing the incidence of the most severe cases by 30 per cent.

Furthermore, the results of clinical studies published by the WHO last April — before the official approval, therefore — had shown that, over a four-year period, this vaccination is capable of preventing four out of ten cases of malaria.

The scale of the results might appear limited, but — as noted by BBC experts in an article on the subject — the vaccine nonetheless represents a success when we consider the complexity of the disease and its effects on the human body.

Malaria
Children play in a waterlogged field in Luanda, Angola, an area where diseases such as malaria, meningitis and tuberculosis are particularly widespread © Luke Dray/Getty Images

A "historic" decision in the fight against malaria

WHO Director-General Tedros Adhanom Ghebreyesus described the approval of the drug as "historic", stating: "The long-awaited malaria vaccine is a breakthrough for science, for child health, and for malaria control."

"The approval gives hope to a continent that bears the worst consequences of this disease," said Matshidiso Moeti, WHO director for Africa. "We therefore expect that in future many children will be able to be protected against malaria."

Malaria
A young girl plays in Luanda, Angola © Luke Dray/Getty Images

Today the main remedies against malaria are still preventive measures, such as insecticides and mosquito nets. Even in cases where the disease follows a relatively mild course, moreover, it is possible — and indeed common — for the mosquitoes carrying the parasite to bite the same person time and again, thereby weakening their immune system and leaving them more vulnerable to other diseases. A safe and effective vaccine could therefore represent a genuine turning point for millions of people.